Adenosine Reduces Cell Surface Expression of Toll-Like Receptor 4 and Inflammation in Response to Lipopolysaccharide and Matrix Products

被引:20
作者
Haas, Benjamin [1 ]
Leonard, Frederique [1 ]
Ernens, Isabelle [1 ]
Rodius, Sophie [1 ]
Vausort, Melanie [1 ]
Rolland-Turner, Magali [1 ]
Devaux, Yvan [1 ]
Wagner, Daniel R. [2 ]
机构
[1] Ctr Rech Publ Sante, Lab Cardiovasc Res, L-1150 Luxembourg, Luxembourg
[2] Ctr Hosp, Div Cardiol, Luxembourg, Luxembourg
关键词
Adenosine; Inflammation; Toll-like receptor 4; Myocardial infarction; Left ventricular remodeling; NECROSIS-FACTOR-ALPHA; ISCHEMIA-REPERFUSION INJURY; MATRIX-METALLOPROTEINASE-9; SECRETION; MYOCARDIAL-INFARCTION; HUMAN MACROPHAGES; A(2A) RECEPTORS; TNF-ALPHA; KAPPA-B; TOLL-LIKE-RECEPTOR-4; ACTIVATION;
D O I
10.1007/s12265-011-9279-x
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Recent evidence suggests that Toll-like receptor 4 (TLR4) is not only involved in innate immunity but is also an important mediator of adverse left ventricular remodeling and heart failure following acute myocardial infarction (MI). TLR4 is activated by lipopolysaccharide (LPS) but also by products of matrix degradation such as hyaluronic acid and heparan sulfate. Although cardioprotective properties of adenosine (Ado) have been extensively studied, its potential to interfere with TLR4 activation is unknown. We observed that TLR4 pathway is activated in white blood cells from MI patients. TLR4 mRNA expression correlated with troponin T levels (R (2) = 0.75; P = 0.01) but not with levels of white blood cells and C-reactive protein. Ado downregulated TLR4 expression at the surface of human macrophages (-50%, P < 0.05). Tumor necrosis factor-alpha production induced by the TLR4 ligands LPS, hyaluronic acid, and heparan sulfate was potently inhibited by Ado (-75% for LPS, P < 0.005). This effect was reproduced by the A2A Ado receptor agonist CGS21680 and the non-selective agonist NECA and was inhibited by the A2A antagonist SCH58261 and the A2A/A2B antagonist ZM241,385. In contrast, Ado induced a 3-fold increase of TLR4 mRNA expression (P = 0.008), revealing the existence of a feedback mechanism to compensate for the loss of TLR4 expression at the cell surface. In conclusion, the TLR4 pathway is activated after MI and correlates with infarct severity but not with the extent of inflammation. Reduction of TLR4 expression by Ado may therefore represent an important strategy to limit remodeling post-MI.
引用
收藏
页码:790 / 800
页数:11
相关论文
共 28 条
[1]
A cell biological view of Toll-like receptor function: regulation through compartmentalization [J].
Barton, Gregory M. ;
Kagan, Jonathan C. .
NATURE REVIEWS IMMUNOLOGY, 2009, 9 (08) :535-542
[2]
CARDIAC NUCLEOTIDES IN HYPOXIA - POSSIBLE ROLE IN REGULATION OF CORONARY BLOOD FLOW [J].
BERNE, RM .
AMERICAN JOURNAL OF PHYSIOLOGY, 1963, 204 (02) :317-&
[3]
Bowlin TL, 1997, CELL MOL BIOL, V43, P345
[4]
Adenosine inhibits matrix metalloproteinase-9 secretion by neutrophils -: Implication of A2a receptor and cAMP/PKA/Ca2+ pathway [J].
Ernens, Isabelle ;
Rouy, Didier ;
Velot, Emilie ;
Devaux, Yvan ;
Wagner, Daniel R. .
CIRCULATION RESEARCH, 2006, 99 (06) :590-597
[5]
Adenosine up-regulates vascular endothelial growth factor in human macrophages [J].
Ernens, Isabelle ;
Leonard, Frederique ;
Vausort, Melanie ;
Rolland-Turner, Magali ;
Devaux, Yvan ;
Wagner, Daniel R. .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 392 (03) :351-356
[6]
Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium [J].
Frantz, S ;
Kobzik, L ;
Kim, YD ;
Fukazawa, R ;
Medzhitov, R ;
Lee, RT ;
Kelly, RA .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (03) :271-280
[7]
Fredholm BB, 2001, PHARMACOL REV, V53, P527
[8]
Hasko G, 1996, J IMMUNOL, V157, P4634
[9]
Adenosine inhibits IL-12 and TNF-α production via adenosine A2a receptor-dependent and independent mechanisms [J].
Haskó, G ;
Kuhel, DG ;
Chen, JF ;
Schwarzschild, MA ;
Deitch, EA ;
Mabley, JG ;
Marton, A ;
Szabó, C .
FASEB JOURNAL, 2000, 14 (13) :2065-2074
[10]
Endocytic pathways regulate Toll-like receptor 4 signaling and link innate and adaptive immunity [J].
Husebye, H ;
Halaas, O ;
Stenmark, H ;
Tunheim, G ;
Sandanger, O ;
Bogen, B ;
Brech, A ;
Latz, E ;
Espevik, T .
EMBO JOURNAL, 2006, 25 (04) :683-692